FI114154B - Förfarande för framställning av terapeutiskt användbar magnesiumomeprazol - Google Patents
Förfarande för framställning av terapeutiskt användbar magnesiumomeprazol Download PDFInfo
- Publication number
- FI114154B FI114154B FI960101A FI960101A FI114154B FI 114154 B FI114154 B FI 114154B FI 960101 A FI960101 A FI 960101A FI 960101 A FI960101 A FI 960101A FI 114154 B FI114154 B FI 114154B
- Authority
- FI
- Finland
- Prior art keywords
- magnesium
- omeprazole
- process according
- determined
- crystals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Contacts (AREA)
- Conductive Materials (AREA)
- Electroplating Methods And Accessories (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Medicinal Preparation (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Powder Metallurgy (AREA)
- Glass Compositions (AREA)
Claims (16)
1. Förfarande för framställning av terapeutiskt användbar magnesiumomeprazol •: · ·: 25 med en kristallinitet som ligger över 70 % vid bestänming med pulverbaserad rönt-. · ·. gendifffaktion, kännetecknat av att följande steg utförs efter varandra: ':": a) att behandla omeprazol eller ett sait därav med magnesiumalkoholat i lösning, . b) att fränskilja oorganiska salter ur reaktionsblandningen, ....: c) att kristallisera magnesiumomeprazol, 114154 d) att isolera den erhällna kristallina magnesiumomeprazolen, och fakultativt e) att rena och torka den kristallina magnesiumomeprazolen pä konventionellt sätt.
2. Förfarande enligt patentkrav 1, kännetecknat av att magnesiumalkoholatet är magnesiummetylalkoholat. 5
3. Förfarande enligt patentkrav 1, kännetecknat av att lösningsmedlet är meta- nol.
4. Förfarande enligt patentkrav 1, kännetecknat av att kristallisationen ästad-kommes genom tillsats av vatten.
5. Förfarande enligt patentkrav 1, kännetecknat av att magnesiumomeprazolen 10 isoleras genom centrifugering av kristalleina.
6. Förfarande enligt patentkrav 1, kännetecknat av att av magnesiumomeprazolen isoleras genom kristallisering följt av filtrering av kristalleina.
7. Förfarande enligt patentkrav 1, kännetecknat av att kristalleina av magnesi-umomeprazol renas genom att kristalleina tvättas med en lösning av polära lös- 15 ningsmedel.
8. Förfarande enligt patentkrav 1, kännetecknat av att kristalleina av magnesi-umomeprazol torkas företrädesvis vid sänkt tryck.
... 9. Förfarande enligt patentkrav 1, kännetecknat av att kristalleina av magnesi- ’ · \ umomeprazol torkas genom att äterstäende lösningsmedel avdrivs genom uppvärm-‘ * 20 ning.
10. Förfarande enligt patentkrav 1, kännetecknat av att man framställer magnesi- . *: ·. umomeprazol med en kristallinitet som ligger över 75 %.
11. Förfarande enligt patentkrav 1, kännetecknat av att man framställer magnesi-umomeprazol med en genomsnittlig komstorlek som vid bestämning med laser- ',,,: 25 difffaktionsteknik är mindre än 30 pm och företrädesvis mindre än 20 pm.
12. Förfarande enligt patentkrav 1, kännetecknat av att man framställer magnesi- S * ft f I ^ Λ * * umomeprazol med en densitet som ligger mellan 1,33 g/cm och 1,35 g/cm vid be- :' ·'; stämning med pulverpyknometer. * 9 114 ib '
13. Förfarande enligt patentkrav 1, kännetecknat av att man framställer magnesi-umomeprazol med en hygroskopicitet som är sadan att viktökningen vid gravimet-risk bestämning är mindre än 2 % vid lagring under en mänad vid upp tili 94 % rela-tiv luftfuktighet. 5
14. Förfarande enligt patentkrav 1, kännetecknat av att man framställer magnesi- umomeprazol med en vattenhalt som ligger mellan 5 och 10 viktprocent vid be-stämning genom titrering enligt Karl Fischer.
15. Förfarande enligt patentkrav 1, kännetecknat av att man framställer magnesi-umomeprazol innehällande mindre än 0,1 viktprocent lösningsmedel vid bestäm- 10 ning med gaskromatografi.
16. Förfarande enligt patentkrav 1, kännetecknat av att man framställer magnesi-umomeprazol innehällande mindre än 0,05 viktprocent lösningsmedel vid bestäm-ning med gaskromatografi. < t · • · · • * · * · * # t »· · < * ·
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE19939302396A SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | A novel compound form |
SE9302396 | 1993-07-09 | ||
SE9400680 | 1994-07-08 | ||
PCT/SE1994/000680 WO1995001977A1 (en) | 1993-07-09 | 1994-07-08 | Magnesium omeprazole |
Publications (3)
Publication Number | Publication Date |
---|---|
FI960101A FI960101A (sv) | 1996-01-09 |
FI960101A0 FI960101A0 (sv) | 1996-01-09 |
FI114154B true FI114154B (sv) | 2004-08-31 |
Family
ID=20390588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI960101A FI114154B (sv) | 1993-07-09 | 1996-01-09 | Förfarande för framställning av terapeutiskt användbar magnesiumomeprazol |
Country Status (42)
Country | Link |
---|---|
US (1) | US5900424A (sv) |
EP (2) | EP0707580B1 (sv) |
JP (2) | JP3635432B2 (sv) |
KR (1) | KR100353783B1 (sv) |
CN (1) | CN1064680C (sv) |
AT (1) | ATE212628T1 (sv) |
AU (1) | AU679766B2 (sv) |
BR (1) | BR9406940A (sv) |
CA (1) | CA2166794C (sv) |
CZ (1) | CZ288933B6 (sv) |
DE (2) | DE69429774T2 (sv) |
DK (1) | DK0707580T3 (sv) |
DZ (1) | DZ1792A1 (sv) |
EE (1) | EE03127B1 (sv) |
EG (1) | EG21437A (sv) |
ES (1) | ES2100136T3 (sv) |
FI (1) | FI114154B (sv) |
GR (1) | GR970300015T1 (sv) |
HK (1) | HK1008329A1 (sv) |
HR (1) | HRP940385B1 (sv) |
HU (1) | HU226861B1 (sv) |
IL (1) | IL110190A (sv) |
IS (1) | IS2075B (sv) |
MA (1) | MA23257A1 (sv) |
MX (1) | MX9405217A (sv) |
MY (1) | MY113274A (sv) |
NO (1) | NO308702B1 (sv) |
NZ (1) | NZ268693A (sv) |
PL (1) | PL175999B1 (sv) |
PT (1) | PT707580E (sv) |
RU (1) | RU2139868C1 (sv) |
SA (1) | SA94150058B1 (sv) |
SE (1) | SE9302396D0 (sv) |
SG (1) | SG52464A1 (sv) |
SI (1) | SI0707580T1 (sv) |
SK (1) | SK281230B6 (sv) |
TN (1) | TNSN94079A1 (sv) |
TW (1) | TW504509B (sv) |
UA (1) | UA43343C2 (sv) |
WO (1) | WO1995001977A1 (sv) |
YU (1) | YU49193B (sv) |
ZA (1) | ZA944933B (sv) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
EE03378B1 (et) * | 1994-07-08 | 2001-04-16 | Astra Aktiebolag | Omeprasooli magneesiumisoola sisaldav peroraalne ravimvorm |
PT1078628E (pt) | 1994-07-08 | 2009-01-27 | Astrazeneca Ab | Forma de dosagem em comprimidos com unidades múltiplas |
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
SE508669C2 (sv) * | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
SE510666C2 (sv) * | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
SE9702000D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
FR2774288B1 (fr) * | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
US6048981A (en) * | 1998-04-22 | 2000-04-11 | Torcan Chemical Ltd. | Magnesium omeprazole and process for its preparation |
DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9803772D0 (sv) | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
IL142703A (en) * | 1998-11-10 | 2006-04-10 | Astrazeneca Ab | Crystalline form of omeprazole |
UA72748C2 (en) | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
IL142629A0 (en) | 1998-11-18 | 2002-03-10 | Astra Ab | Improved chemical process and pharmaceutical formulation |
TWI243672B (en) | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
CA2290893C (en) * | 1999-11-16 | 2007-05-01 | Bernard Charles Sherman | Magnesium omeprazole |
SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
AU5248601A (en) * | 2000-05-15 | 2001-11-26 | Ranbaxy Laboratories Limited | Novel amorphous form of omeprazole salts |
CA2386716C (en) * | 2002-05-17 | 2012-07-24 | Bernard Charles Sherman | Magnesium salt of s-omeprazole |
CA2417311C (en) | 2000-08-04 | 2012-07-10 | Takeda Chemical Industries, Ltd. | Crystalline alkali metal salts of lansoprazole and their production and use |
US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
AU2001296908A1 (en) * | 2000-09-29 | 2002-04-08 | Geneva Pharmaceuticals, Inc. | Proton pump inhibitor formulation |
SE0101379D0 (sv) | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
CA2472103A1 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
FR2836228B1 (fr) * | 2002-02-21 | 2005-08-19 | Inst Francais Du Petrole | Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
EP1603537A4 (en) * | 2003-02-20 | 2009-11-04 | Santarus Inc | IMMEDIATE RELEASE OF OMEPRAZOLE ANTACIDAL COMPLEX WITH NEW FORMULATION FOR RAPID AND PROLONGED ELIMINATION OF GASTRIC ACID |
CN1842525A (zh) * | 2003-05-05 | 2006-10-04 | 兰贝克赛实验室有限公司 | 苯并咪唑衍生物的钡盐 |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
AU2004257864A1 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
JP2006528181A (ja) * | 2003-07-18 | 2006-12-14 | サンタラス インコーポレイティッド | 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法 |
KR20060092255A (ko) | 2003-09-26 | 2006-08-22 | 알자 코포레이션 | 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법 |
WO2005082888A1 (en) * | 2004-03-01 | 2005-09-09 | Milen Merkez Ilac Endustrisi A.S. | Process for the preparation of magnesium salt of omeprazole |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
ES2246149B1 (es) * | 2004-07-02 | 2007-06-01 | Esteve Quimica, S.A. | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
US20060024362A1 (en) * | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
WO2006067599A2 (en) | 2004-12-23 | 2006-06-29 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
WO2006073779A1 (en) * | 2004-12-30 | 2006-07-13 | Transform Phamaceuticals, Inc. | Novel omeprazole forms and related methods |
EP1845982A2 (en) * | 2005-02-02 | 2007-10-24 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions prepared by non-aqueous layering process |
US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂 |
EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
US7553857B2 (en) | 2005-12-23 | 2009-06-30 | Lek Pharmaceuticals D.D. | S-omeprazole magnesium |
EP2026768B1 (en) * | 2006-06-01 | 2018-02-28 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
PL2046334T3 (pl) | 2006-07-25 | 2015-02-27 | Vecta Ltd | Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
WO2008067037A2 (en) | 2006-10-05 | 2008-06-05 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
EP2086543A2 (en) | 2006-10-27 | 2009-08-12 | The Curators of the University of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
EP1947099A1 (en) | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
US8911787B2 (en) | 2008-02-26 | 2014-12-16 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
JP5302389B2 (ja) | 2008-04-29 | 2013-10-02 | エフ.ホフマン−ラ ロシュ アーゲー | Jnkのピリミジニルピリドンインヒビター |
WO2009137648A1 (en) * | 2008-05-09 | 2009-11-12 | Aptapharma, Inc. | Multilayer proton pump inhibitor tablets |
US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
EP2147918A1 (en) | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
AU2009290712A1 (en) | 2008-09-09 | 2010-03-18 | Astrazeneca Ab | Method for delivering a pharmaceutical composition to patient in need thereof |
WO2010122583A2 (en) | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
MX2012000057A (es) * | 2009-06-25 | 2012-06-01 | Pozen Inc | Metodo para tratar a un paciente con necesidad de terapia de aspirina. |
WO2010151216A1 (en) | 2009-06-25 | 2010-12-29 | Astrazeneca Ab | Method for treating a patient at risk for developing an nsaid-associated ulcer |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2519229A2 (en) | 2009-12-29 | 2012-11-07 | Novartis AG | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2345408A3 (en) | 2010-01-08 | 2012-02-29 | Dr. Reddy's Laboratories Ltd. | Acid labile drug formulations |
EP2601947A1 (en) | 2011-12-05 | 2013-06-12 | Abo Bakr Mohammed Ali Al-Mehdar | Fixed-dose combination for treatment of helicobacter pylori associated diseases |
CA2860231A1 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
CN102993184A (zh) * | 2013-01-08 | 2013-03-27 | 湖南方盛制药股份有限公司 | 一种埃索美拉唑及其镁盐三水合物的制备方法 |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
DE4035455A1 (de) * | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
-
1993
- 1993-07-09 SE SE19939302396A patent/SE9302396D0/sv unknown
-
1994
- 1994-06-23 TW TW083105710A patent/TW504509B/zh not_active IP Right Cessation
- 1994-07-01 HR HR940385A patent/HRP940385B1/xx not_active IP Right Cessation
- 1994-07-01 IL IL11019094A patent/IL110190A/xx not_active IP Right Cessation
- 1994-07-04 SA SA94150058A patent/SA94150058B1/ar unknown
- 1994-07-05 IS IS4186A patent/IS2075B/is unknown
- 1994-07-07 MY MYPI94001774A patent/MY113274A/en unknown
- 1994-07-07 ZA ZA944933A patent/ZA944933B/xx unknown
- 1994-07-07 MA MA23567A patent/MA23257A1/fr unknown
- 1994-07-07 EG EG40794A patent/EG21437A/xx active
- 1994-07-08 SK SK22-96A patent/SK281230B6/sk not_active IP Right Cessation
- 1994-07-08 UA UA96010059A patent/UA43343C2/uk unknown
- 1994-07-08 PL PL94312440A patent/PL175999B1/pl unknown
- 1994-07-08 SG SG1996004887A patent/SG52464A1/en unknown
- 1994-07-08 AU AU71981/94A patent/AU679766B2/en not_active Expired
- 1994-07-08 YU YU43694A patent/YU49193B/sh unknown
- 1994-07-08 TN TNTNSN94079A patent/TNSN94079A1/fr unknown
- 1994-07-08 JP JP50400595A patent/JP3635432B2/ja not_active Expired - Lifetime
- 1994-07-08 HU HU9503873A patent/HU226861B1/hu unknown
- 1994-07-08 ES ES94921154T patent/ES2100136T3/es not_active Expired - Lifetime
- 1994-07-08 KR KR1019960700051A patent/KR100353783B1/ko not_active IP Right Cessation
- 1994-07-08 US US08/313,342 patent/US5900424A/en not_active Expired - Lifetime
- 1994-07-08 PT PT94921154T patent/PT707580E/pt unknown
- 1994-07-08 DE DE69429774T patent/DE69429774T2/de not_active Expired - Lifetime
- 1994-07-08 EP EP94921154A patent/EP0707580B1/en not_active Expired - Lifetime
- 1994-07-08 EP EP01117362A patent/EP1164132A3/en not_active Withdrawn
- 1994-07-08 DK DK94921154T patent/DK0707580T3/da active
- 1994-07-08 CA CA002166794A patent/CA2166794C/en not_active Expired - Lifetime
- 1994-07-08 AT AT94921154T patent/ATE212628T1/de active
- 1994-07-08 DE DE0707580T patent/DE707580T1/de active Pending
- 1994-07-08 SI SI9430414T patent/SI0707580T1/xx unknown
- 1994-07-08 CN CN94192733A patent/CN1064680C/zh not_active Expired - Lifetime
- 1994-07-08 NZ NZ268693A patent/NZ268693A/en not_active IP Right Cessation
- 1994-07-08 RU RU96102079A patent/RU2139868C1/ru active
- 1994-07-08 CZ CZ199669A patent/CZ288933B6/cs not_active IP Right Cessation
- 1994-07-08 MX MX9405217A patent/MX9405217A/es unknown
- 1994-07-08 WO PCT/SE1994/000680 patent/WO1995001977A1/en active IP Right Grant
- 1994-07-08 BR BR9406940A patent/BR9406940A/pt not_active Application Discontinuation
- 1994-11-17 EE EE9400405A patent/EE03127B1/xx unknown
- 1994-11-27 DZ DZ940071A patent/DZ1792A1/fr active
-
1996
- 1996-01-05 NO NO960068A patent/NO308702B1/no not_active IP Right Cessation
- 1996-01-09 FI FI960101A patent/FI114154B/sv not_active IP Right Cessation
-
1997
- 1997-05-30 GR GR970300015T patent/GR970300015T1/el unknown
-
1998
- 1998-07-17 HK HK98109227A patent/HK1008329A1/xx not_active IP Right Cessation
-
2001
- 2001-09-26 JP JP2001293480A patent/JP3878826B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI114154B (sv) | Förfarande för framställning av terapeutiskt användbar magnesiumomeprazol | |
WO1995001977A9 (en) | Magnesium omeprazole | |
FI91263B (sv) | Förfarande för framställning av azitromycindihydrat | |
CA2521391C (en) | Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate | |
CS274420B2 (en) | Method of clock-wise isomer alpha-(4,5,6,7-tetrahydrothieno (3,2-c)-5-pyridyl)-)2-chlorphenyl) methylacetate production | |
JP2006504618A (ja) | 非結晶性及び結晶性ロサルタン・カリウム、及びそれらの調製方法 | |
KR100774271B1 (ko) | 발라사이클로비르 염산염의 결정질 형태 | |
RU2385325C2 (ru) | Способ получения сульфата атазанавира | |
NO317304B1 (no) | Tetrahydropyridoetere | |
RU2088584C1 (ru) | Кристаллический полугидрат 4-(5,6,7,8-тетрагидроимидазо [1,5-а]пиридин-5-ил)-бензонитрил-гидрохлорида | |
KR20030042038A (ko) | 온단세트론 히드로클로라이드의 신규한 결정 형태 및용매화물 형태와 이들의 제조 방법 | |
WO2000078729A1 (en) | Crystalline forms of lansoprazole | |
US4668674A (en) | (+)-6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)-acetyl]-11H-dibenzo[b,][1,4]diazepin-11-one, the isolation thereof and its use as a pharmaceutical material | |
SU1279530A3 (ru) | Способ получени замещенных пиррол или пиридо /2,1- @ / хиназолинов или их солей | |
JPH06192228A (ja) | 結晶性(r)−(−)−2−シクロヘプチル−n−メチルスルフオニル−[4−(2−キノリニルメトキシ)−フエニル]−アセトアミド | |
US4094988A (en) | Method of treating gastric ulcers using 5,6-dihydro-1,4-dithiinoxides | |
LU82527A1 (fr) | Nouveaux pyridylaminotriazoles et composition pharmaceutique les contenant | |
JPH08239381A (ja) | 安定なベンズイミダゾール誘導体金属塩の溶媒和物及びその製造法並びにそれを含有する抗潰瘍剤 | |
FR2523972A1 (fr) | Derives vinyliques substitues de la 1h-pyrazolo-(1,5-a) pyrimidine utiles notamment comme medicaments antiulcerigenes et antisecretoires gastriques et procede de leur preparation | |
RU2002748C1 (ru) | Способ получени 2,3,4,5-тетрагидро-5-метил-2-[(5-метил-1Н-имидазол-4-ил)метил]-1Н-пиридо(4,3-в)индол-1-она или его соли | |
TW200827357A (en) | Improved process for the manufacture of mirtazapine | |
CN116143709A (zh) | 丹酚酸a衍生物的新晶型及其制备方法 | |
MXPA01004794A (en) | Crystalline forms of 3-(2, 4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide | |
ZA200403582B (en) | Amorphous and crystalline forms of losartan potassium and process for their preparation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |